NewsBenzingaArriVent Announced Sunday, Initial Phase 1 Data For CDH17-Targeted ADC ARR-217 In Gastrointestinal Cancers At ESMO, Demonstrating 44.8% Objective Response Rate At 6mg/kg Dose In Late-Line Colorectal Cancer Patients ArriVent Announced Sunday, Initial Phase 1 Data For CDH17-Targeted ADC ARR-217 In Gastrointestinal Cancers At ESMO, Demonstrating 44.8% Objective Response Rate At 6mg/kg Dose In Late-Line Colorectal Cancer Patients Benzinga 2026.10.25 17:59 (GMT+0) Open on Benzinga Other news Ionis Pharmaceuticals: Compelling Long-Term Commercial Upside (NASDAQ:IONS) Comcast Q3 Results Show Peacock and Wireless Gains Amid Widening Broadband Losses REITs Rebound As Earnings Deliver Lam Research: Down 29% Since My Sell Call, But The Math Has Changed (Upgrade) (LRCX) Nvidia Teams Up With 6 Supply Chain Partners to Expand Its Global AI Manufacturing Capacity Financial Times Reported Sunday, Bon Secours Mercy Health In Late-Stage Talks To Acquire Majority Stake In Surgery Partners For ~$20/Share; Deal Would be Valued At ~$6B Including Debt
Financial Times Reported Sunday, Bon Secours Mercy Health In Late-Stage Talks To Acquire Majority Stake In Surgery Partners For ~$20/Share; Deal Would be Valued At ~$6B Including Debt
